A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer

This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy compared with chemotherapy alone in subjects with previously untreated metastatic breast cancer.

Study Overview

• Status: Unknown
• Conditions: Metastatic Breast Cancer
• Intervention / Treatment: Drug: Bevacizumab; Drug: Chemotherapy; Drug: Placebo

Detailed Description

This study includes a blinded treatment phase, an optional open-label post-progression phase, and a survival follow-up phase. During the blinded treatment phase, patients receive chemotherapy and study drug (bevacizumab or placebo) every 3 weeks until disease progression, treatment-limiting toxicity, or death due to any cause. The optional open-label post-progression phase consists of chemotherapy treatment (per investigator discretion) and optional treatment with open-label bevacizumab. Patients who complete the study or who discontinue from treatment (regardless of participation in the optional open-label post-progression phase) will be followed for survival and subsequent anti-cancer therapies every 4 months until death, withdrawal of consent, loss to follow-up, or study termination. Patients who discontinue from treatment during the blinded treatment phase for reasons other than disease progression will have tumor assessments every 9 weeks until documented disease progression or death.

• Study Type: Interventional
• Enrollment (Actual): 1237
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Geelong, Australia, 3220
  • Malvern, Australia, 3144
  • Melbourne, Australia, 3002
  • Perth, Australia, 6008
  • Southport, Australia, 4215
  • Wahroonga, Australia, 2076
  • Waratah, Australia, 2298
  • Wollongong, Australia, 2500
• Brazil
  • Porto Alegre, Brazil, 91350-200
  • Rio de Janeiro, Brazil, 22260-020
  • Salvador, Brazil, 40170-110
  • Santo Andre, Brazil, 09060-870
  • Sao Paulo, Brazil, 03102-002
• Canada
  • Manitoba
    • Winnipeg, Manitoba, Canada, R2H 2A6
  • Quebec
    • Montreal, Quebec, Canada, H2W 1S6
    • Montreal, Quebec, Canada, H2L 4M1
• France
  • Marseille, France, 13273
  • Paris, France, 75248
  • Reims, France, 51100
  • Saint Herblain, France, 44805
  • Strasbourg, France, 67010
• Greece
  • Athens, Greece, 11521
  • Hania, Greece, 73300
  • Heraklion, Greece, 71110
  • Patras, Greece, 26500
  • Thessaloniki, Greece, 57001
• Guatemala
  • Guatemala City, Guatemala, 01015
• Korea, Republic of
  • Kyunggi-do, Korea, Republic of, 411-769
  • Seoul, Korea, Republic of, 110-744
  • Seoul, Korea, Republic of, 120-752
• Mexico
  • Acapulco, Mexico, 39670
  • Aguascalientes, Mexico, 20230
  • Merida, Mexico, 97500
  • Monterrey, Mexico, 64020
  • Monterrey, Mexico, 64380
• Netherlands
  • Amstelveen, Netherlands, 1186 AH
  • Apeldoorn, Netherlands, 7334 DZ
  • Delft, Netherlands, 2600 GA
• Norway
  • Oslo, Norway, 0407
  • Oslo, Norway, 0310
• Panama
  • Panama City, Panama
• Peru
  • Callao, Peru
• Philippines
  • Quezon City, Philippines, 1114
• Russian Federation
  • Chelyabinsk, Russian Federation, 454 087
  • Ivanovo, Russian Federation, 153040
  • Kazan, Russian Federation, 420029
  • Kazan, Russian Federation, 420111
  • Moscow, Russian Federation, 115478
  • Moscow, Russian Federation, 129128
  • Moscow, Russian Federation, 117837
  • Novosibirsk, Russian Federation, 630047
  • Obninsk, Russian Federation, 249036
  • Ryazan, Russian Federation, 390011
  • Samara, Russian Federation, 443066
  • St Petersburg, Russian Federation, 197758
  • UFA, Russian Federation, 450054
• Singapore
  • Singapore, Singapore, 119228
  • Singapore, Singapore, 169610
• Spain
  • Córdoba, Spain, 14004
  • Elche, Spain, 03203
  • Girona, Spain, 17007
  • La Coruna, Spain, 15006
  • La Laguna, Spain, 38320
  • Madrid, Spain, 28034
  • Santander, Spain, 39008
  • Sevilla, Spain, 41013
  • Valencia, Spain, 46010
  • Zaragoza, Spain, 50009
• Sweden
  • Gaevle, Sweden, 80187
  • Uppsala, Sweden, 751 85
  • Örebro, Sweden, 701 85
• Taiwan
  • Tainan, Taiwan, 704
  • Taoyuan, Taiwan, 333
• Ukraine
  • Cherkassy, Ukraine, 18009
  • Dnipropetrovsk, Ukraine, 49102
  • Kiev, Ukraine, 03115
  • Lvov, Ukraine, 79031
  • Odessa, Ukraine, 65055
  • Zaporozhye, Ukraine, 69104
• United Kingdom
  • Chelsmford, United Kingdom, CM1 7ET
  • Cottingham, United Kingdom, HU16 5JQ
  • Epping, United Kingdom, CM16 6TN
  • Huddersfield, United Kingdom, HD3 3EA
  • Nottingham, United Kingdom, NG5 1PB
  • Sheffield, United Kingdom, S1O 2SJ
  • Swansea, United Kingdom, SA2 8QA
• United States
  • California
    • Fullerton, California, United States, 92835
    • Santa Barbara, California, United States, 93105
  • Iowa
    • Iowa City, Iowa, United States, 52242
    • Sioux City, Iowa, United States, 51101
  • Kansas
    • Wichita, Kansas, United States, 67214-3728
• Uruguay
  • Montevideo, Uruguay, 11200

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologically or cytologically confirmed adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease.
• Signed Informed Consent Form.
• Age ≥ 18 years.
• For women of childbearing potential, use of accepted and effective method of non-hormonal contraception.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Ability and capacity to comply with study and follow-up procedures.
• For anthracycline cohort only: Adequate left ventricular function at study entry, defined as a left ventricular ejection fraction (LVEF) ≥ 50% by either multigated acquisition (MUGA) scan scan or echocardiography (ECHO).
• For subjects who have received recent radiation therapy, recovery prior to baseline (Day 0) from any significant (Grade ≥ 3) acute toxicity.

Exclusion Criteria:

• Unknown human epidermal growth factor receptor 2 (HER2) status or known HER2-positive status.
• Prior chemotherapy for locally recurrent or metastatic disease.
• Prior hormonal therapy less than 1 week prior to Day 0.
• Prior adjuvant or neoadjuvant chemotherapy within 12 months prior to Day 0.
• For anthracycline cohort only: Prior anthracycline as part of neoadjuvant or adjuvant therapy for localized breast cancer.
• Investigational therapy within 28 days of Day 0.
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study.
• Minor surgical procedures, such as fine needle aspirations or core biopsies, within 7 days prior to Day 0.
• Prior therapy with bevacizumab, sorafenib, sunitinib, or other vascular endothelial growth factor (VEGF) pathway-targeted therapy.
• Known brain or other central nervous system (CNS) metastases.
• Blood pressure of > 150/100 mmHg.
• Unstable angina.
• New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF).
• History of myocardial infarction within 6 months prior to Day 0.
• History of stroke or transient ischemic attack within 6 months prior to Day 0.
• Clinically significant peripheral vascular disease.
• Evidence of bleeding diathesis or coagulopathy.
• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0.
• Serious non-healing wound, ulcer, or bone fracture.
• Pregnancy (positive serum pregnancy test) or lactation.
• Inadequate organ function, as evidenced by any of the following laboratory values: Absolute neutrophil count < 1500/uL; platelet count < 100,000/uL; total bilirubin > 1.5 mg/dL; alkaline phosphatase, AST, and/or ALT > 2x upper limit of normal (ULN) (> 5x ULN in subjects with known liver or, for alkaline phosphatase elevations, bone involvement); alkaline phosphatase > 2x ULN (> 7x ULN in subjects with known bone involvement); serum creatinine > 2.0 mg/dL; partial thromboplastin time (PTT) and/or either international normalized ratio (INR) or prothrombin time (PT) > 1.5x upper limit of normal (except for subjects receiving anti-coagulation therapy); urine protein/creatinine ratio > 1.0 at screening for U.S. subjects, or urine dipstick for proteinuria >/= 1+ at screening followed by 24-hour urine collection demonstrating > 1 g protein/24 hr for ex-U.S. subjects.
• Uncontrolled serious medical or psychiatric illness.
• Active infection requiring intravenous (iv) antibiotics at Day 0.
• History of other malignancies within 5 years of Day 0 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix (subjects with a history of bilateral breast cancer will be eligible).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Bevacizumab + chemotherapy; Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.	Drug: Bevacizumab; Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.; Other Names: Avastin; Drug: Chemotherapy; The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles. Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle; Docetaxel 75-100 mg/m^2 IV; Paclitaxel protein-bound particles (Abraxane®) 260 mg/m^2 IV Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle; 5-fluorouracil 500 mg/m^2 IV + epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV; 5-fluorouracil 500 mg/m^2 IV + doxorubicin 50 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV; Doxorubicin 50-60 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV; Epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle
Placebo Comparator: Placebo + chemotherapy; Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.	Drug: Chemotherapy; The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles. Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle; Docetaxel 75-100 mg/m^2 IV; Paclitaxel protein-bound particles (Abraxane®) 260 mg/m^2 IV Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle; 5-fluorouracil 500 mg/m^2 IV + epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV; 5-fluorouracil 500 mg/m^2 IV + doxorubicin 50 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV; Doxorubicin 50-60 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV; Epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle; Drug: Placebo; Placebo consisted of the vehicle for bevacizumab without the antibody.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)	PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.	Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)	An objective response was defined as a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart as determined by the investigator using RECIST. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.	Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
Duration of Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)	Duration of objective response was defined as the time from the first tumor assessment that led to a determination of an objective response to the time of disease progression or death due to any cause, whichever occurred first.	Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
Overall Survival	Overall survival was defined as the time from randomization until death from any cause.	Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
1-year Survival	1-year survival was defined as the percentage of patients who were alive 1 year after randomization. The percentage of patients alive at 1 year was determined using Kaplan-Meier analyses and the 95% confidence intervals were computed using the Brookmeyer-Crowley method.	Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
Progression-free Survival (PFS) as Determined by the Independent Review Committee Using Response Evaluation Criteria in Solid Tumors (RECIST)	PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the Independent Review Committee using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.	Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)

Collaborators and Investigators

• Sponsor: Genentech, Inc.
• Investigators: Study Director: Leonardo Faoro, MD, Genentech, Inc.

Publications and helpful links

General Publications

• Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. J Clin Oncol. 2018 Apr 20;36(12):1225-1231. doi: 10.1200/JCO.2017.74.6917. Epub 2018 Mar 9.

Study record dates

Study Major Dates

• Study Start: December 1, 2005
• Primary Completion (Actual): July 1, 2008
• Study Completion (Anticipated): December 1, 2013

Study Registration Dates

• First Submitted: December 2, 2005
• First Submitted That Met QC Criteria: December 2, 2005
• First Posted (Estimate): December 6, 2005

Study Record Updates

• Last Update Posted (Estimate): December 13, 2013
• Last Update Submitted That Met QC Criteria: November 18, 2013
• Last Verified: November 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Bevacizumab
• Other Study ID Numbers: AVF3694g; BO20094 (Other Identifier: Hoffmann-La Roche)